

*“Pearls”
of
Veterinary Medicine*



*Trusted By
The Profession
Since 1981*

PRODUCTS & SERVICES

General Information.....	1
Brokers, Consolidators, Recruiters & Opportunities	1
Continuing Education	1
Diagnostics & Laboratory Services.....	1
Diets.....	2
Diets, Therapeutic	2
Drugs & Therapeutics.....	3
Equipment	4
Drugs & Therapeutics.....	Error! Bookmark not defined.
Insurance.....	4
Monitoring Devices	4
Pet Supplies	4
Practice Management	4
Services.....	4
Supplements	4
Website Design & IT Services	6

General Information

The companies and products featured in this issue are new additions to our Perpetual Product Guide, which you can access [here](#).

Brokers, Consolidators, Recruiters & Opportunities

Blue Sky - [BlueSky at-home](#), obtained the records of **TheVets and BetterVet** that closed 7/21/2025.

Dutch - [dutch.com](#) - “Affordable vet care when you need it.” Offers 10-minute video calls with licensed veterinarians who then can prescribe medications. Annual plans are \$132 (2026 pricing).

Modern Animal - [modernanimal.com](#). “A network of small animal clinics that deliver best-in-class care by prioritizing the learning and development of our teams and simplifying their workflows with technology.”

Continuing Education

VetMedTeam - [vetmedteam.com](#). Offers free and paid RACE approved, on-demand CE for veterinarians and technicians, including a free 2 hour “[Controlled Drugs: Recordkeeping and Diversion Prevention in Veterinary Medicine](#)” which may be useful for vets in those states requiring controlled drug CE.

Vet Together - see under Practice Management

Diagnostics & Laboratory Services

Bronson Animal Disease Laboratory - [Tests & Fees webpage](#). 321-697-1467.

Comprehensive diagnostic lab with very reasonable pricing.

Fidocure - [fidocure.com](#), [support@fidocure.com](#)

The FidoCure platform utilizes next-generation sequencing (NGS) of 48 canine cancer genes to integrate genomic profiles with clinical outcomes. Data from over 2,000 cases indicate that somatic mutations—such as TP53, PIK3CA, and BRAF—carry prognostic significance and inform therapeutic selection. Research suggests that incorporating small-molecule targeted inhibitors alongside standard treatments such as doxorubicin may enhance survival rates in specific gene-drug pairings. Examples of better outcomes include the use of rapamycin in PIK3CA- or TP53-mutant tumors, vorinostat in TP53-mutant tumors, lapatinib in BRAF-mutant tumors, trametinib in ARID1A-mutant tumors, or dasatinib in BRCA1-mutant tumors. By leveraging canine cancers as translational models for human precision oncology, FidoCure provides veterinarians with evidence-based therapeutic recommendations while developing a comprehensive clinico-genomic database to advance biomarker-driven oncology.

Fidocure is also available in the IDEXX FidoCure® DNA Sequencing Panel Add-on to Biopsy (Test code 8978, list price \$914.85 in 2026) which may only be added on to a

